Huidong Gu

List of Publications by Year
in descending order

31 papers	905 citations	430874 18 h-index	477307 29 g-index
35 all docs	35 docs citations	35 times ranked	1029 citing authors

#	ARTICLE	IF	CITATIONS
1	Application of in-sample calibration curve methodology for regulated bioanalysis: Critical considerations in method development, validation and sample analysis. Journal of Pharmaceutical and Biomedical Analysis, 2020, 177, 112844.	2.8	9
2	Antipeptide Immunocapture with In-Sample Calibration Curve Strategy for Sensitive and Robust LC-MS/MS Bioanalysis of Clinical Protein Biomarkers in Formalin-Fixed Paraffin-Embedded Tumor Tissues. Analytical Chemistry, 2020, 92, 14713-14722.	6.5	15
3	Fit-for-purpose protein biomarker assay validation strategies using hybrid immunocapture-liquid chromatography-tandem-mass spectrometry platform: Quantitative analysis of total soluble cluster of differentiation 73. Analytica Chimica Acta, 2020, 1126, 144-153.	5.4	7
4	Modeling and Simulation of the Pharmacokinetics and Target Engagement of an Antagonist Monoclonal Antibody to Interferonâ€Î³â€"Induced Protein 10, BMSâ€"986184, in Healthy Participants to Guide Therapeutic Dosing. Clinical Pharmacology in Drug Development, 2020, 9, 689-698.	1.6	2
5	Eliminating Preparation of Multisample External Calibration Curves and Dilution of Study Samples Using the Multiple Isotopologue Reaction Monitoring (MIRM) Technique in Quantitative LC-MS/MS Bioanalysis. Analytical Chemistry, 2019, 91, 8652-8659.	6.5	17
6	Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS. Analytical Chemistry, 2019, 91, 8443-8452.	6.5	10
7	In-Sample Calibration Curve Using Multiple Isotopologue Reaction Monitoring of a Stable Isotopically Labeled Analyte for Instant LC-MS/MS Bioanalysis and Quantitative Proteomics. Analytical Chemistry, 2019, 91, 2536-2543.	6.5	20
8	Opportunities and challenges for hybrid immunoaffinity LCâ€"MS approach for quantitative analysis of protein biomarkers. Future Science OA, 2018, 4, FSO281.	1.9	8
9	Critical considerations for immunocapture enrichment LCâ€"MS bioanalysis of protein therapeutics and biomarkers. Bioanalysis, 2018, 10, 987-995.	1.5	10
10	Role of regional absorption and gastrointestinal motility on variability in oral absorption of a model drug. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 117, 333-345.	4.3	4
11	Immunoaffinity LCâ€"MS/MS for quantitative determination of a free and total protein target as a target engagement biomarker. Bioanalysis, 2017, 9, 1573-1588.	1.5	23
12	Antibodyâ€"drug conjugate bioanalysis using LB-LCâ€"MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays. Bioanalysis, 2016, 8, 1383-1401.	1.5	33
13	Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LCâ€"MS/MS approach: Assay development, validation, and a case study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1002, 54-62.	2.3	56
14	An integrated multiplatform bioanalytical strategy for antibodyâ€"drug conjugates: a novel case study. Bioanalysis, 2015, 7, 1569-1582.	1.5	29
15	Challenges and solutions in the bioanalysis of BMS-986094 and its metabolites including a highly polar, active nucleoside triphosphate in plasma and tissues using LCâ€"MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2015, 1000, 29-40.	2.3	7
16	Selecting the Correct Weighting Factors for Linear and Quadratic Calibration Curves with Least-Squares Regression Algorithm in Bioanalytical LC-MS/MS Assays and Impacts of Using Incorrect Weighting Factors on Curve Stability, Data Quality, and Assay Performance. Analytical Chemistry, 2014, 86, 8959-8966.	6.5	165
17	Development of a validated liquid chromatography tandem mass spectrometry assay for a PEGylated adnectin in cynomolgus monkey plasma using protein precipitation and trypsin digestion. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 934, 1-7.	2.3	21
18	A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50â€ƒmg oral dose of the Î³â€"secretase inhibitor avagacestat. British Journal of Clinical Pharmacology, 2013, 75, 136-145.	2.4	13

#	Article	IF	Citations
19	Effects of sub-chronic donepezil on brain Abeta and cognition in a mouse model of Alzheimer's disease. Psychopharmacology, 2013, 230, 279-289.	3.1	28
20	Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men. Clinical Drug Investigation, 2012, 32, 761-769.	2.2	35
21	A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects. Clinical Pharmacokinetics, 2012, 51, 681-693.	3.5	47
22	Practical and Efficient Strategy for Evaluating Oral Absolute Bioavailability with an Intravenous Microdose of a Stable Isotopically-Labeled Drug Using a Selected Reaction Monitoring Mass Spectrometry Assay. Analytical Chemistry, 2012, 84, 10031-10037.	6.5	39
23	Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding at low concentrations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 889-890, 77-86.	2.3	27
24	Calculation and Mitigation of Isotopic Interferences in Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Assays and Its Application in Supporting Microdose Absolute Bioavailability Studies. Analytical Chemistry, 2012, 84, 4844-4850.	6.5	35
25	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers. Clinical Therapeutics, 2012, 34, 654-667.	2.5	62
26	Development and validation of sensitive and selective LC–MS/MS methods for the determination of BMS-708163, a γ-secretase inhibitor, in plasma and cerebrospinal fluid using deprotonated or formate adduct ions as precursor ions. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2319-2326.	2.3	27
27	Effect of mobile phase pH, aqueous–organic ratio, and buffer concentration on electrospray ionization tandem mass spectrometric fragmentation patterns: implications in liquid chromatography/tandem mass spectrometric bioanalysis. Rapid Communications in Mass Spectrometry, 2010, 24, 3221-3229.	1.5	36
28	Validated LC–MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma. Bioanalysis, 2010, 2, 2001-2009.	1.5	44
29	Automated Tecan Programming for Bioanalytical Sample Preparation with EZTecan. Assay and Drug Development Technologies, 2006, 4, 721-733.	1.2	13
30	Pulsed laser deposition of NiTi shape memory alloy thin films with optimum parameters. Thin Solid Films, 1998, 330, 196-201.	1.8	19
31	Room-temperature growth of high-purity titanium nitride by laser ablation of titanium in a nitrogen atmosphere. Surface and Coatings Technology, 1998, 110, 153-157.	4.8	11